Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Farmers Insurance
Cipla
Teva
Daiichi Sankyo
US Department of Justice
US Army
Chubb
Express Scripts
Colorcon

Generated: August 17, 2018

DrugPatentWatch Database Preview

Merck And Co Inc Company Profile

« Back to Dashboard

What is the competitive landscape for MERCK AND CO INC, and when can generic versions of MERCK AND CO INC drugs launch?

MERCK AND CO INC has two approved drugs.

There is one US patent protecting MERCK AND CO INC drugs.

There are thirty-six patent family members on MERCK AND CO INC drugs in twenty-seven countries and two supplementary protection certificates in two countries.

Summary for Merck And Co Inc
International Patents:36
US Patents:1
Tradenames:2
Ingredients:2
NDAs:2
Drug Master File Entries: 13

Drugs and US Patents for Merck And Co Inc

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Merck And Co Inc FOSAMAX alendronate sodium TABLET;ORAL 020560-001 Sep 29, 1995 DISCN Yes No ➤ Try a Free Trial ➤ Try a Free Trial
Merck And Co Inc EMEND fosaprepitant dimeglumine POWDER;INTRAVENOUS 022023-002 Nov 12, 2010 AP RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial
Merck And Co Inc EMEND fosaprepitant dimeglumine POWDER;INTRAVENOUS 022023-001 Jan 25, 2008 DISCN Yes No 5,691,336*PED ➤ Try a Free Trial Y ➤ Try a Free Trial
Merck And Co Inc EMEND fosaprepitant dimeglumine POWDER;INTRAVENOUS 022023-001 Jan 25, 2008 DISCN Yes No ➤ Try a Free Trial ➤ Try a Free Trial
Merck And Co Inc EMEND fosaprepitant dimeglumine POWDER;INTRAVENOUS 022023-002 Nov 12, 2010 AP RX Yes Yes 5,691,336*PED ➤ Try a Free Trial Y ➤ Try a Free Trial
Merck And Co Inc FOSAMAX alendronate sodium TABLET;ORAL 020560-004 Oct 20, 2000 DISCN Yes No ➤ Try a Free Trial ➤ Try a Free Trial
Merck And Co Inc FOSAMAX alendronate sodium TABLET;ORAL 020560-003 Apr 25, 1997 DISCN Yes No ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Expired US Patents for Merck And Co Inc

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Merck And Co Inc FOSAMAX alendronate sodium TABLET;ORAL 020560-004 Oct 20, 2000 5,681,590*PED ➤ Try a Free Trial
Merck And Co Inc FOSAMAX alendronate sodium TABLET;ORAL 020560-003 Apr 25, 1997 5,804,570 ➤ Try a Free Trial
Merck And Co Inc FOSAMAX alendronate sodium TABLET;ORAL 020560-001 Sep 29, 1995 6,194,004*PED ➤ Try a Free Trial
Merck And Co Inc FOSAMAX alendronate sodium TABLET;ORAL 020560-005 Oct 20, 2000 5,681,590*PED ➤ Try a Free Trial
Merck And Co Inc FOSAMAX alendronate sodium TABLET;ORAL 020560-003 Apr 25, 1997 5,994,329 ➤ Try a Free Trial
Merck And Co Inc FOSAMAX alendronate sodium TABLET;ORAL 020560-002 Sep 29, 1995 5,804,570 ➤ Try a Free Trial
Merck And Co Inc EMEND fosaprepitant dimeglumine POWDER;INTRAVENOUS 022023-002 Nov 12, 2010 5,716,942 ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Paragraph IV (Patent) Challenges for MERCK AND CO INC drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Capsule 40 mg, 80 mg and 125 mg ➤ Subscribe 2008-11-03
➤ Subscribe Injection 150 mg/vial ➤ Subscribe 2012-01-25
➤ Subscribe Oral Solution 70 mg/75 mL ➤ Subscribe 2007-09-07
➤ Subscribe Injection 115 mg/vial ➤ Subscribe 2012-01-25
➤ Subscribe for Oral Suspension 125 mg/Kit ➤ Subscribe 2016-11-23

Non-Orange Book US Patents for Merck And Co Inc

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,512,570 Treatment of emesis with morpholine tachykinin receptor antagonists ➤ Try a Free Trial
5,780,467 Morpholine compounds are prodrugs useful as tachykinin receptor antagonists ➤ Try a Free Trial
5,716,942 Treatment of migraine with morpholine tachykinin receptor antagonists ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

International Patents for Merck And Co Inc Drugs

Country Document Number Estimated Expiration
Croatia P950099 ➤ Try a Free Trial
Japan 3073770 ➤ Try a Free Trial
Bulgaria 100798 ➤ Try a Free Trial
Mexico 9603845 ➤ Try a Free Trial
Japan H09509935 ➤ Try a Free Trial
Germany 69528823 ➤ Try a Free Trial
Russian Federation 2170233 ➤ Try a Free Trial
Country Document Number Estimated Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Supplementary Protection Certificates for Merck And Co Inc Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C0019 France ➤ Try a Free Trial PRODUCT NAME: FOSAPREPITANT DIMEGLUMINE; REGISTRATION NO/DATE: EU/1/07/437/001 20080111
C/GB08/021 United Kingdom ➤ Try a Free Trial PRODUCT NAME: FOSAPREPITANT AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, IN PARTICULAR THE BIS(N-METHYL-D-GLUCAMINE)SALT; REGISTERED: UK EU/1/07/437/001 20080111; UK EU/1/07/437/002 20080111
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Covington
UBS
Medtronic
Dow
Baxter
Cipla
Fish and Richardson
Julphar
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.